Imaging outcome measures for progressive multiple sclerosis trials

Molecular and Metabolic Imaging in Multiple Sclerosis

(2017) Marcello Moccia et al.   NEUROIMAGING CLINICS OF NORTH AMERICA

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis

(2016) Robert J. Fox et al.   Contemporary Clinical Trials

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis

(2016) Hyunwoo Lee et al.   Multiple Sclerosis Journal

High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial

(2016) Karen Schreiber et al.   Multiple Sclerosis Journal

Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome

(2016) WJ Brownlee et al.   Multiple Sclerosis Journal

Imaging as an Outcome Measure in Multiple Sclerosis

(2016) Daniel Ontaneda et al.   Neurotherapeutics

Progressive MS Alliance Industry Forum: Maximizing Collective Impact To Enable Drug Development

(2016) P. Zaratin et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Fully automated grey and white matter spinal cord segmentation

(2016) Ferran Prados et al.   Scientific Reports

Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis

(2016) Hyunwoo Lee et al.   Multiple Sclerosis Journal

High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial

(2016) Karen Schreiber et al.   Multiple Sclerosis Journal

Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome

(2016) WJ Brownlee et al.   Multiple Sclerosis Journal

Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method

(2016) Veronica Popescu et al.   PLoS One

The neuronal component of gray matter damage in multiple sclerosis: A [11C]flumazenil positron emission tomography study

(2015) Léorah Freeman et al.   ANNALS OF NEUROLOGY

Positron-emission tomography molecular imaging of glia and myelin in drug discovery for multiple sclerosis

(2015) Paul M Matthews et al.   Expert Opinion on Drug Discovery

MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis

(2015) Achim Gass et al.   LANCET NEUROLOGY

Nonconventional MRI and microstructural cerebral changes in multiple sclerosis

(2015) Christian Enzinger et al.   Nature Reviews Neurology

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients

(2015)   Nature Reviews Neurology

Can leptomeningeal enhancement be linked to multiple sclerosis?

(2015) F. Barkhof et al.   NEUROLOGY

Multi-centre reproducibility of diffusion MRI parameters for clinical sequences in the brain

(2015) Matthew Grech-Sollars et al.   NMR IN BIOMEDICINE

Advanced imaging tools to investigate multiple sclerosis pathology

(2015) Benedetta Bodini et al.   PRESSE MEDICALE

Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial

(2015) Claire M. Rice et al.   Trials

PET imaging in multiple sclerosis

(2014) Daniele de Paula Faria et al.   Journal of Neuroimmune Pharmacology

Imaging outcomes for trials of remyelination in multiple sclerosis

(2014) Shahrukh Mallik et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis

(2014) H Kearney et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

(2014) Jeremy Chataway et al.   LANCET

Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis

(2014) Manuel A. Friese et al.   Nature Reviews Neurology

Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial

(2014) J. Romme Christensen et al.   NEUROLOGY

Fluoxetine in Progressive Multiple Sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial

(2014) Melissa Cambron et al.   Trials

Correlation between brain volume change and T2 relaxation time induced by dehydration and rehydration: Implications for monitoring atrophy in clinical studies

(2014) Kunio Nakamura et al.   NeuroImage-Clinical

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

(2013) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY

Improved MRI quantification of spinal cord atrophy in multiple sclerosis

(2013) Hugh Kearney et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Brain atrophy and lesion load predict long term disability in multiple sclerosis

(2013) Veronica Popescu et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage

(2013) M. Filippi et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

(2013) Krzysztof Selmaj et al.   LANCET NEUROLOGY

Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial

(2013) John Zajicek et al.   LANCET NEUROLOGY

MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials

(2013) Maria Pia Sormani et al.   LANCET NEUROLOGY

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

(2013) Jerry S Wolinsky et al.   Multiple Sclerosis Journal

Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration

(2013) H Kearney et al.   Multiple Sclerosis Journal

Relevance of Spinal Cord Abnormalities to Clinical Disability in Multiple Sclerosis: MR Imaging Findings in a Large Cohort of Patients

(2013) Carsten Lukas et al.   RADIOLOGY

Reliability of Longitudinal Brain Volume Loss Measurements between 2 Sites in Patients with Multiple Sclerosis: Comparison of 7 Quantification Techniques

(2012) F. Durand-Dubief et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Interferon   for secondary progressive multiple sclerosis: a systematic review

(2012) L. L. Mantia et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

(2012) Peter Connick et al.   LANCET NEUROLOGY

The role of advanced magnetic resonance imaging techniques in primary progressive MS

(2011) Maria A. Rocca et al.   JOURNAL OF NEUROLOGY

A multicenter assessment of cervical cord atrophy among MS clinical phenotypes

(2011) M. A. Rocca et al.   NEUROLOGY

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS

(2011) M. S. Freedman et al.   NEUROLOGY

Modeling the Distribution of New MRI Cortical Lesions in Multiple Sclerosis Longitudinal Studies

(2011) Maria Pia Sormani et al.   PLoS One

A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis

(2010) J. Furby et al.   JOURNAL OF NEUROLOGY

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial

(2010) Raju Kapoor et al.   LANCET NEUROLOGY

Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis

(2010) IJ van den Elskamp et al.   Multiple Sclerosis Journal

Lesion enhancement diminishes with time in primary progressive multiple sclerosis

(2010) Z. Khaleeli et al.   Multiple Sclerosis Journal

A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis

(2010) Jeremy Chataway et al.   Multiple Sclerosis Journal

Disease modeling in multiple sclerosis: Assessment and quantification of sources of variability in brain parenchymal fraction measurements

(2010) Mehul P. Sampat et al.   NEUROIMAGE

Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis

(2010) I. J. van den Elskamp et al.   NEURORADIOLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Advances in the molecular imaging of multiple sclerosis

(2009) Paul M Matthews et al.   Expert Review of Clinical Immunology

Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis

(2009) B Healy et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis

(2009) X. Montalban et al.   Multiple Sclerosis Journal

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

(2009) Frederik Barkhof et al.   Nature Reviews Neurology

Gray matter atrophy is related to long-term disability in multiple sclerosis

(2008) Leonora K. Fisniku et al.   ANNALS OF NEUROLOGY

Predicting progression in primary progressive multiple sclerosis: A 10-year multicenter study

(2008) Zhaleh Khaleeli et al.   ANNALS OF NEUROLOGY

A Preliminary Validation Study of Diffusion Tensor Imaging as a Measure of Functional Brain Injury

(2008) Robert J. Fox et al.   ARCHIVES OF NEUROLOGY

Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis

(2008) Marco Rovaris et al.   Multiple Sclerosis Journal

Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography

(2008) F Costello et al.   Multiple Sclerosis Journal

Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis

(2008) D. R. Altmann et al.   NEUROLOGY

Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study

(2007) B.R. Sajja et al.   Multiple Sclerosis Journal